Cargando…

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer

BACKGROUND: Programmed cell death protein 1 (PD‐1) blockade plus radiotherapy may be a promising strategy to improve the prognosis of patients with metastatic non‐small cell lung cancer (NSCLC). However, the optimum combined scheme, treatment time of radiotherapy, and irradiated lesion have not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zi‐Chao, Chen, Kai‐Yan, Li, Na, Xie, Ming‐Ying, Sheng, Jia‐Min, Fan, Yun, Huang, Zhi‐Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376180/
https://www.ncbi.nlm.nih.gov/pubmed/35762488
http://dx.doi.org/10.1111/1759-7714.14553
_version_ 1784768109530316800
author Zhou, Zi‐Chao
Chen, Kai‐Yan
Li, Na
Xie, Ming‐Ying
Sheng, Jia‐Min
Fan, Yun
Huang, Zhi‐Yu
author_facet Zhou, Zi‐Chao
Chen, Kai‐Yan
Li, Na
Xie, Ming‐Ying
Sheng, Jia‐Min
Fan, Yun
Huang, Zhi‐Yu
author_sort Zhou, Zi‐Chao
collection PubMed
description BACKGROUND: Programmed cell death protein 1 (PD‐1) blockade plus radiotherapy may be a promising strategy to improve the prognosis of patients with metastatic non‐small cell lung cancer (NSCLC). However, the optimum combined scheme, treatment time of radiotherapy, and irradiated lesion have not been fully determined. METHODS: A total of 321 metastatic NSCLC patients treated with immunotherapy were identified. Among them, 107 patients received PD‐1/PD‐ligand 1 (PD‐L1) inhibitors with radiotherapy, while the remaining cases did not receive radiotherapy. Data on overall survival (OS), progression‐free survival (PFS), treatment response and adverse events were collected. Comparisons based on type of radiation, timing of radiotherapy and number of irradiated lesions were performed. RESULTS: The median OS in PD‐1/PD‐L1 inhibitors plus radiotherapy was longer than in nonradiotherapy (22.8 vs. 16.6 months, p = 0.022). The median PFS showed a similar trend in this study (9.4 vs. 6.2 months, p = 0.042). Moreover, the combined strategy demonstrated a superior disease control rate and abscopal control rate versus without radiotherapy (both p ≤ 0.001). Further multivariate analysis in the immunotherapy and radiotherapy groups revealed that age below 65 (p = 0.004), Eastern Cooperative Oncology Group performance scores of 0–1 (p = 0.001), oligometastasis (p = 0.006), concurrent combination (p = 0.002), and treated with SRT (p = 0.013) were associated with longer OS. There was a similar incidence of adverse events between the two groups (both p ≥ 0.05). CONCLUSIONS: The combination of PD‐1/PD‐L1 inhibitors plus palliative radiotherapy demonstrated favorable survival and good tolerability in metastatic NSCLC patients.
format Online
Article
Text
id pubmed-9376180
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-93761802022-08-18 Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer Zhou, Zi‐Chao Chen, Kai‐Yan Li, Na Xie, Ming‐Ying Sheng, Jia‐Min Fan, Yun Huang, Zhi‐Yu Thorac Cancer Original Articles BACKGROUND: Programmed cell death protein 1 (PD‐1) blockade plus radiotherapy may be a promising strategy to improve the prognosis of patients with metastatic non‐small cell lung cancer (NSCLC). However, the optimum combined scheme, treatment time of radiotherapy, and irradiated lesion have not been fully determined. METHODS: A total of 321 metastatic NSCLC patients treated with immunotherapy were identified. Among them, 107 patients received PD‐1/PD‐ligand 1 (PD‐L1) inhibitors with radiotherapy, while the remaining cases did not receive radiotherapy. Data on overall survival (OS), progression‐free survival (PFS), treatment response and adverse events were collected. Comparisons based on type of radiation, timing of radiotherapy and number of irradiated lesions were performed. RESULTS: The median OS in PD‐1/PD‐L1 inhibitors plus radiotherapy was longer than in nonradiotherapy (22.8 vs. 16.6 months, p = 0.022). The median PFS showed a similar trend in this study (9.4 vs. 6.2 months, p = 0.042). Moreover, the combined strategy demonstrated a superior disease control rate and abscopal control rate versus without radiotherapy (both p ≤ 0.001). Further multivariate analysis in the immunotherapy and radiotherapy groups revealed that age below 65 (p = 0.004), Eastern Cooperative Oncology Group performance scores of 0–1 (p = 0.001), oligometastasis (p = 0.006), concurrent combination (p = 0.002), and treated with SRT (p = 0.013) were associated with longer OS. There was a similar incidence of adverse events between the two groups (both p ≥ 0.05). CONCLUSIONS: The combination of PD‐1/PD‐L1 inhibitors plus palliative radiotherapy demonstrated favorable survival and good tolerability in metastatic NSCLC patients. John Wiley & Sons Australia, Ltd 2022-06-28 2022-08 /pmc/articles/PMC9376180/ /pubmed/35762488 http://dx.doi.org/10.1111/1759-7714.14553 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Zhou, Zi‐Chao
Chen, Kai‐Yan
Li, Na
Xie, Ming‐Ying
Sheng, Jia‐Min
Fan, Yun
Huang, Zhi‐Yu
Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
title Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
title_full Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
title_fullStr Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
title_full_unstemmed Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
title_short Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
title_sort real‐world utilization of pd‐1/pd‐l1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376180/
https://www.ncbi.nlm.nih.gov/pubmed/35762488
http://dx.doi.org/10.1111/1759-7714.14553
work_keys_str_mv AT zhouzichao realworldutilizationofpd1pdl1inhibitorswithpalliativeradiotherapyinpatientswithmetastaticnonsmallcelllungcancer
AT chenkaiyan realworldutilizationofpd1pdl1inhibitorswithpalliativeradiotherapyinpatientswithmetastaticnonsmallcelllungcancer
AT lina realworldutilizationofpd1pdl1inhibitorswithpalliativeradiotherapyinpatientswithmetastaticnonsmallcelllungcancer
AT xiemingying realworldutilizationofpd1pdl1inhibitorswithpalliativeradiotherapyinpatientswithmetastaticnonsmallcelllungcancer
AT shengjiamin realworldutilizationofpd1pdl1inhibitorswithpalliativeradiotherapyinpatientswithmetastaticnonsmallcelllungcancer
AT fanyun realworldutilizationofpd1pdl1inhibitorswithpalliativeradiotherapyinpatientswithmetastaticnonsmallcelllungcancer
AT huangzhiyu realworldutilizationofpd1pdl1inhibitorswithpalliativeradiotherapyinpatientswithmetastaticnonsmallcelllungcancer